Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05545969
Title Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)
Acronym Neo PeLeMM
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Melanoma Institute Australia
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.